This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / j j reports positive phase 3 data for nipocalimab fo

JNJ - J&J reports positive phase 3 data for nipocalimab for neuromuscular disease

June, 28 2024 12:45 PM Johnson & Johnson

2024-06-28 12:45:53 ET

More on Johnson & Johnson

J&J mid-stage trial for Tremfya against immune disorder fails
Johnson & Johnson closes acquisition of biotechnology company Proteologix
Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Johnson & Johnson: Market Will Regret The Overreaction
Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)

For further details see:

J&J reports positive phase 3 data for nipocalimab for neuromuscular disease

Stock Information

Company Name:	Johnson & Johnson
Stock Symbol:	JNJ
Market:	NYSE
Website:	johnson.ca

JNJ JNJ Quote JNJ Short JNJ News JNJ Articles JNJ Message Board

Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.